日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial

贝利木单抗对狼疮性肾炎患者肾脏相关结局的影响：BLISS-LN 3期试验的事后亚组分析

期刊:Nephrology Dialysis Transplantation
影响因子:5.6
doi:10.1093/ndt/gfad167
Anders, Hans-Joachim; Furie, Richard; Malvar, Ana; Zhao, Ming-Hui; Hiromura, Keiju; Weinmann-Menke, Julia; Green, Yulia; Jones-Leone, Angela; Negrini, Daniela; Levy, Roger A; Lightstone, Liz; Tanaka, Yoshiya; Rovin, Brad H
肾炎
发表日期：2023
文献求助 收藏

MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT

MOONLIGHT 研究：一项比较贝利木单抗在既往有狼疮性肾炎病史的患者中疗效的研究设计，该研究基于贝利木单抗上市后疗效 cOhOrt 和日本狼疮全国注册研究 (LUNA) coHorT。

期刊:Lupus Science & Medicine
影响因子:3.5
doi:10.1136/lupus-2022-000746
Sada, Kenei; Kurita, Noriaki; Noma, Hisashi; Matsuki, Taizo; Quasny, Holly; Levy, Roger A; Jones-Leone, Angela R; Gairy, Kerry; Yajima, Nobuyuki
肾炎
发表日期：2022
文献求助 收藏

10 Years of belimumab experience: What have we learnt?

贝利尤单抗10年应用经验：我们学到了什么？

期刊:Lupus
影响因子:1.9
doi:10.1177/09612033211028653
Levy, Roger A; Gonzalez-Rivera, Tania; Khamashta, Munther; Fox, Norma Lynn; Jones-Leone, Angela; Rubin, Bernie; Burriss, Susan W; Gairy, Kerry; Maurik, Andre van; Roth, David A
发表日期：2021
文献求助 收藏

The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis

基线BLyS水平和I型干扰素诱导基因特征状态在决定系统性红斑狼疮患者贝利木单抗疗效中的作用：一项事后荟萃分析

期刊:Arthritis Research & Therapy
影响因子:4.6
doi:10.1186/s13075-020-02177-0
Wilkinson, Christel; Henderson, Robert B; Jones-Leone, Angela R; Flint, Shaun M; Lennon, Mark; Levy, Roger A; Ji, Beulah; Bass, Damon L; Roth, David
红斑狼疮
免疫/内分泌
发表日期：2020
文献求助 收藏

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

每周一次GLP-1受体激动剂阿必鲁肽的疗效和安全性（HARMONY 2）：一项针对饮食和运动控制不佳的2型糖尿病患者的随机、安慰剂对照试验的52周主要终点结果

期刊:Diabetologia
影响因子:10.2
doi:10.1007/s00125-015-3795-1
Nauck, Michael A; Stewart, Murray W; Perkins, Christopher; Jones-Leone, Angela; Yang, Fred; Perry, Caroline; Reinhardt, Rickey R; Rendell, Marc
糖尿病
信号转导
GLP-1
代谢
发表日期：2016
文献求助 收藏